PhRMA CEO Links Press Coverage of High Prices and the Need for Generic Competition

The head of the brand-name pharmaceutical industry’s trade group called for streamlining of the generics approval process, and a greater shift to value-based payments.

PhRMA CEO Stephen Ubl directly named Turing, Valeant and Mylan as companies drawing negative media attention over the past year, saying their common denominator has been older, off-patent medicines facing a lack of generic competition.

“It may seem odd for the branded industry to talk about the form of the generic approval process, but we need to have targeted changes that address those issues,” he said, during an event hosted by PhRMA and The Atlantic in Boston.